Online inquiry

IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12761MR)

This product GTTS-WQ12761MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NOTCH1 gene. The antibody can be applied in Lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_017617.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4851
UniProt ID P46531
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12761MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11272MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ9193MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ11624MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ10227MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ11135MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ15703MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ15367MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ12419MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW